Boiron's Camilia Tummy Receives Top Honors from Baby Innovation Awards
Newtown Square, Pennsylvania--(Newsfile Corp. - June 26, 2025) - Camilia Tummy® has received the "Baby Accessory Product of the Year" in the 2025 Baby Innovation Awards. Now in its fifth year, this independent awards program highlights the most innovative companies, services, and products in the...
2025-06-26 2:00 PM EDT | Boiron USA
Canadian Institute of Actuaries Announces Alicia Rollo as New Executive Director
Ottawa, Ontario--(Newsfile Corp. - June 26, 2025) - As the Canadian Institute of Actuaries (CIA) looks to the future, it welcomes new leadership, celebrates a legacy of service and shares key milestones in its continued advancement of the actuarial profession in Canada. Alicia Rollo appointed...
Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-26 12:00 PM EDT | Canadian Institute of Actuaries / FR: Institut canadien des actuaires
L'Institut canadien des actuaires annonce la nomination d'Alicia Rollo au poste de directrice générale
Ottawa, Ontario--(Newsfile Corp. - 26 juin 2025) - Se tournant vers l'avenir, l'Institut canadien des actuaires accueille une nouvelle dirigeante, célèbre un héritage de service et partage des jalons importants de la progression soutenue de la profession actuarielle au Canada. Nomination d'Alicia...
Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-26 12:00 PM EDT | Canadian Institute of Actuaries / FR: Institut canadien des actuaires
Liviniti Achieves HITRUST i1 Certification for Industry-Leading Security Practices
Natchitoches, Louisiana--(Newsfile Corp. - June 26, 2025) - Liviniti, a national leader in PBM transparency and prescription drug savings, today announced it has achieved 2025 certified HITRUST status for information security. Platforms with HITRUST certification include the Liviniti client...
2025-06-26 9:08 AM EDT | Liviniti
Hemostemix Announces Lead Order of $1,500,000 and the Full Repayment of $2,500,000 Convertible Debenture
Calgary, Alberta--(Newsfile Corp. - June 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces its Chairman, Peter Lacey, has provided the Company with a lead order for a non brokered private placement in the amount of $1,500,000 for Units at...
Biotechnology, Pharmaceuticals, Health
2025-06-26 9:00 AM EDT | Hemostemix Inc.
Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States
Fiscal year 2025 revenue of $108.3 million, record net income of $2.2 million, operating income of $8.2 million, and record Adjusted EBITDA* of $20.2 million US commercial launch of GRAFAPEX™ executed in February 2025, following swiftly on the FDA's approval in January 2025, with initial...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-25 6:15 PM EDT | Medexus Pharmaceuticals Inc.
Unbuzzd Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzdTM – the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms - is...
2025-06-25 8:30 AM EDT | Unbuzzd Wellness Inc.
InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced...
Biotechnology, Pharmaceuticals
2025-06-25 8:00 AM EDT | InMed Pharmaceuticals
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort
Marlborough, Massachusetts--(Newsfile Corp. - June 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that the Safety...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-25 7:45 AM EDT | Phio Pharmaceuticals Corp.
PreveCeutical Announces Date for Annual General and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has scheduled its annual general and special meeting for August 15, 2025, at which the shareholders...
Biotechnology, Pharmaceuticals, Health
2025-06-25 7:00 AM EDT | PreveCeutical Medical Inc.